Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation

Clinical Transplantation

Volumn 27, Issue 4, 2013, Pages

  Zallio, Francesco ^a   Primon, Valeria ^a   Tamiazzo, Stefania ^a   Pini, Massimo ^a   Baraldi, Anna ^a   Corsetti, Maria T ^a   Gotta, Franca ^a   Bertassello, Claudia ^a   Salvi, Flavia ^a   Rocchetti, Andrea ^a   Levis, Alessandro ^a  

^a C Arrigo Children's Hospital   (Italy)

Author keywords

Cytomegalovirus; Epstein Barr virus; Hematopoietic stem cell transplantation; Post transplant lymphoproliferative disease; Rituximab

Indexed keywords

CYCLOSPORIN; CYTOMEGALOVIRUS ANTIGEN PP65; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; THYMOCYTE ANTIBODY; VIRUS DNA;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; CYTOMEGALOVIRUS; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOABLATIVE CONDITIONING; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT DISEASE; REDUCED INTENSITY CONDITIONING; RESPIRATORY FAILURE; RISK FACTOR; SIBLING; SINGLE DRUG DOSE; T CELL DEPLETION; UNRELATED DONORS; VIRUS LOAD; VIRUS REACTIVATION;

CYTOMEGALOVIRUS; EPSTEIN-BARR VIRUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE; RITUXIMAB;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; COHORT STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; VIRUS ACTIVATION; YOUNG ADULT;

EID: 84881541462     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12172     Document Type: Article

References (27)

1. Gottschalk S, Rooney CM, Heslop HE. Posttransplant lymphoproliferative disorders. Annu Rev Med 2005: 56: 29.
2. Landgren O, Gilbert ES, Rizzo JD et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009: 113: 4992.
3. Mañez R, Breinig MC, Linden P et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 1997: 176: 1462.
4. Mattila PS, Aalto SM, Heikkilä L et al. Malignancies after heart transplantation: presence of Epstein-Barr virus and cytomegalovirus. Clin Transplant 2001: 15: 337.
5. Curtis RE, Travis LB, Rowlings PA et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999: 94: 2208.
6. Cesaro S, Murrone A, Mengoli C et al. The real-time polymerase chain reaction guided modulation of immunosuppression enables the preemptive management of Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2005: 128: 224.
7. Van Esser JW, Hubert G, Niesters M et al. Prevention of Epstein-Barr virus lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002: 99: 4364.
8. Coppoletta S, Tedone E, Galano B et al. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011: 17: 901.
9. Bollard CM, Rooney CM, Heslop HE. T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol 2012: 9: 510.
10. Heslop HE. How I treat EBV lymphoproliferation. Blood 2009: 114: 4002.
11. Weinstock DM, Ambrossi GC, Brennam C et al. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant 2006: 37: 539.
12. Niesters GM, Van Esser F, Fries E et al. Development of a real-time quantitative assay for detection of Epstein-Barr Virus. J Clin Microbiol 2000: 38: 712.
13. Volfova P, Lengerova M, Winterova J et al. Monitoring of Epstein-Barr virus load in patients after allogeneic hematopoietic stem cell transplantation. Infection 2012: 40: 583.
14. Peric Z, Cahu X, Chevallier P et al. Features of Epstein-Barr virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation. Leukemia 2011: 25: 932.
15. Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009: 113: 23.
16. Jaffe ES, Harris NL, Stein H et al. eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001.
17. Sundin M, Le Blanc K, Ringden O et al. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post transplant lymphoproliferative disorders following allogenic hematopoietic stem cell transplantation. Haematologica 1059: 2006: 91.
18. Juvonen E, Aalto SM, Tarkkanen J et al. Retrospective evaluation of serum Epstein-Barr virus DNA levels in 406 allogenic stem cell transplant patients. Haematologica 2007: 92: 819.
19. Gustafsson A, Levitsky V, Zou JZ et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of specific cytotoxic T cells. Blood 2000: 95: 807.
20. Styczynski J, Einsele H, Gil L. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 2009: 11: 383.
21. Ljungman P. Molecular monitoring of viral infections after hematopoietic stem cell transplantation. Int J Hematol 2010: 91: 596.
22. Wagner HJ, Cheng YC, Huls MH et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004: 103: 3979.
23. Ahmad I, Cau NV, Kwan J et al. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation. Transplantation 2009: 87: 1240.
24. Stevens SJ, Verschuuren EA, Pronk I et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001: 97: 1165.
25. Kasztelewicz B, Jankowska I, Pawlsowska J et al. Epstein-Barr virus DNA load in peripheral blood mononuclear cells and whole blood from pediatric transplant recipients. Transpl Infect Dis 2011: 13: 471.
26. Baldanti F, Gatti M, Furione M et al. Kinetics of Epstein-Barr virus DNA load in different blood compartments of pediatric recipients of T-cell depleted HLA-haploidentical stem cell transplantation. J Clin Microbiol 2008: 46: 3672.
27. Raccomandazioni per la diagnosi e la terapia delle linfoproliferazioni EBV-associate nel trapianto di cellule staminali emopoietiche. Available at: http://www.gitmo.it/linee-guida-e-procedure.